Literature DB >> 24982090

Placental transfer of darunavir in an ex vivo human cotyledon perfusion model.

Laurent Mandelbrot1, Dominique Duro2, Emilie Belissa3, Gilles Peytavin3.   

Abstract

Placental transfer of the HIV protease inhibitor darunavir was investigated in 5 term human cotyledons perfused with darunavir (1,000 ng/ml) in the maternal to fetal direction. The mean (± the standard deviation [SD]) fetal transfer rate (FTR) (fetal/maternal concentration at steady state from 30 to 90 min) was 15.0%±2.1%, and the mean (±SD) clearance index (darunavir FTR/antipyrine FTR) was 40.3%±5.8%. This shows that darunavir crosses the placenta at a relatively low rate, resulting in fetal exposure.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24982090      PMCID： PMC4135808          DOI： 10.1128/AAC.03184-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  31 in total

1.  Use of darunavir/ritonavir once daily in treatment-naive pregnant woman: pharmacokinetics, compartmental exposure, efficacy and safety.

Authors:  Jelena Ivanovic; Rita Bellagamba; Emanuele Nicastri; Fabrizio Signore; Cristina Vallone; Massimo Tempestilli; Chiara Tommasi; Luisa Mazzitelli; Pasquale Narciso
Journal:  AIDS       Date:  2010-04-24       Impact factor: 4.177

2.  Decreased plasma levels of darunavir/ritonavir in a vertically infected pregnant woman carrying multiclass-resistant HIV type-1.

Authors:  Carmela Pinnetti; Enrica Tamburrini; Enzo Ragazzoni; Andrea De Luca; Pierluigi Navarra
Journal:  Antivir Ther       Date:  2010

3.  P-glycoprotein expression of the human placenta during pregnancy.

Authors:  S Gil; R Saura; F Forestier; R Farinotti
Journal:  Placenta       Date:  2005 Feb-Mar       Impact factor: 3.481

4.  Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.

Authors:  Laurent Mandelbrot; Fabienne Mazy; Corinne Floch-Tudal; Françoise Meier; Elie Azria; Catherine Crenn-Hebert; Jean Marc Treluyer; Evelyne Herinomenzanahary; Claudia Ferreira; Gilles Peytavin
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2011-04-13       Impact factor: 2.435

5.  Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers.

Authors:  Albane Simon; Josiane Warszawski; Dulanjalee Kariyawasam; Jerome Le Chenadec; Valerie Benhammou; Paul Czernichow; Frantz Foissac; Kathleen Laborde; Jean-Marc Tréluyer; Ghislaine Firtion; Inès Layouni; Martine Munzer; Françoise Bavoux; Michel Polak; Stéphane Blanche
Journal:  JAMA       Date:  2011-07-06       Impact factor: 56.272

6.  Transfer across the perfused human placenta of antipyrine, sodium and leucine.

Authors:  H Schneider; M Panigel; J Dancis
Journal:  Am J Obstet Gynecol       Date:  1972-11-15       Impact factor: 8.661

7.  Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.

Authors:  R S Sperling; D E Shapiro; R W Coombs; J A Todd; S A Herman; G D McSherry; M J O'Sullivan; R B Van Dyke; E Jimenez; C Rouzioux; P M Flynn; J L Sullivan
Journal:  N Engl J Med       Date:  1996-11-28       Impact factor: 91.245

8.  Reduced lopinavir exposure during pregnancy.

Authors:  Alice M Stek; Mark Mirochnick; Edmund Capparelli; Brookie M Best; Chengcheng Hu; Sandra K Burchett; Carol Elgie; Diane T Holland; Elizabeth Smith; Ruth Tuomala; Amanda Cotter; Jennifer S Read
Journal:  AIDS       Date:  2006-10-03       Impact factor: 4.177

9.  Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model.

Authors:  F Forestier; P de Renty; G Peytavin; E Dohin; R Farinotti; L Mandelbrot
Journal:  Am J Obstet Gynecol       Date:  2001-07       Impact factor: 8.661

10.  Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.

Authors:  Diego Ripamonti; Dario Cattaneo; Franco Maggiolo; Monica Airoldi; Luigi Frigerio; Pierangelo Bertuletti; Maurizio Ruggeri; Fredy Suter
Journal:  AIDS       Date:  2007-11-30       Impact factor: 4.177
View more
  6 in total

1.  Placental transfer of rilpivirine in an ex vivo human cotyledon perfusion model.

Authors:  Laurent Mandelbrot; Dominique Duro; Emilie Belissa; Gilles Peytavin
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

2.  Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon Perfusion Model.

Authors:  Cécile Vinot; Jean-Marc Tréluyer; Carole Giraud; Laurent Gavard; Gilles Peytavin; Laurent Mandelbrot
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

3.  Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling.

Authors:  Stein Schalkwijk; Aaron O Buaben; Jolien J M Freriksen; Angela P Colbers; David M Burger; Rick Greupink; Frans G M Russel
Journal:  Clin Pharmacokinet       Date:  2018-06       Impact factor: 6.447

4.  Placental transfer and tissue accumulation of dolutegravir in the ex vivo human cotyledon perfusion model.

Authors:  Laurent Mandelbrot; Pierre-François Ceccaldi; Dominique Duro; Minh Lê; Lucile Pencolé; Gilles Peytavin
Journal:  PLoS One       Date:  2019-08-13       Impact factor: 3.240

5.  Placental transfer of Letermovir & Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection.

Authors:  Valentine Faure Bardon; Gilles Peytavin; Minh Patrick Lê; Tiffany Guilleminot; Elisabeth Elefant; Julien Stirnemann; Marianne Leruez-Ville; Yves Ville
Journal:  PLoS One       Date:  2020-04-30       Impact factor: 3.240

Review 6.  Placental transfer and safety in pregnancy of medications under investigation to treat coronavirus disease 2019.

Authors:  Margaux Louchet; Jeanne Sibiude; Gilles Peytavin; Olivier Picone; Jean-Marc Tréluyer; Laurent Mandelbrot
Journal:  Am J Obstet Gynecol MFM       Date:  2020-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.